ResMed

RMD

Market cap $37.3B

IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner.

ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and significant cash reserves position it favorably for investors who want to protect their portfolio for a recession. RMD's operational efficiency and cash balance support continued dividend growth and potential buybacks.

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds.

RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.

ResMed Inc. (NYSE:RMD) reported better-than-expected earnings for the first quarter on Thursday.

ResMed Inc. ( RMD ) Q1 2026 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Sallilyn Schwartz - Chief Investor Relations Officer Michael Farrell - CEO & Chairman Brett Sandercock - Chief Financial Officer Conference Call Participants Davinthra Thillainathan - Goldman Sachs Group, Inc., Research Division Laura Sutcliffe - Citigroup Inc. Exchange Research Saul Hadassin - Barrenjoey Markets Pty Limited, Research Division Lyanne Harrison - BofA Securities, Research Division Steven Wheen - Jarden Limited, Research Division David Bailey - Morgan Stanley, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division Dan Hurren - MST Financial Services Pty Limited, Research Division Presentation Operator Hello, and welcome to the Q1 Fiscal Year 2026 ResMed Earnings Conference Call. My name is Kevin.

While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.49 per share. This compares to earnings of $2.2 per share a year ago.

Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis  Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% Income from operations increased 15%; non-GAAP income from operations up 19% Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55 Operating cash flow of $457 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2025.

Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.